Navigation Links
Tragara Pharmaceuticals' Apricoxib Reverses EMT, a Key Process for Cancer Progression and Metastasis
Date:5/26/2011

versal also reduced proliferation and survival of tumor cells in the primary lesion, perhaps due to a reduction in levels of cancer stem cells which are thought to arise via EMT."

The Capoxigem posters, originally presented earlier in 2011 and available on the Tragara company website, are:

2011 AACR 102nd Annual Meeting (April 4, 2011)

"Inhibition of COX-2 with Apricoxib Enhances the Efficacy of Standard Therapy in Preclinical Models of Human Pancreatic Cancer", Amanda R. Kirane, Ph.D., University of Texas Southwestern Medical Center, Dallas.

2011 ASCO Gastrointestinal Cancers Symposium (January 22, 2011)

"Preclinical Antitumor Activity and Mechanisms of Action of Apricoxib, a Clinical Cox-2 Inhibitor", Francis Burrows, Ph.D., Tragara Pharmaceuticals, Inc., San Diego.

About Epithelial-Mesenchymal Transition (EMT) and COX-2

The epithelial-mesenchymal transition (EMT) is a developmental program resulting in a cellular shift from an epithelial phenotype to a motile, mesenchymal form that is essential for embryogenesis, tissue remodeling and tumor progression. Under the influence of oncogenic factors such as inflammatory cytokines, polarized epithelial cancer cells detach from their underlying basement membrane and progressively lose lineage-specific markers such as E-cadherin and acquire mesenchymal markers (e.g. vimentin) and the ability to invade and metastasize to new sites. Both EMT and hyperactivity of the COX-2 pathway are associated with poor prognosis in a range of solid tumor types. Many of the properties of solid tumor cells that have undergone EMT, including apoptosis resistance and heightened angiogenic and metastatic capacity, are also associated with chronic inflammation and overexpression of COX-2 and its
'/>"/>

SOURCE Tragara Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014  Veran ... company, announced today the positive, cost-effective final ... innovative SPiNPerc™ procedure. The SPiNPerc endobronchial percutaneous ... a percutaneous approach to biopsy when a ... patients and physicians experience positive financial outcomes ...
(Date:7/10/2014)... , July 10, 2014  The U.S. Department ... three-year grant to University Hospitals (UH) Case Medical Center ... new national model aimed at improving care for patients ... Care," the project will test a unique model developed ... with late-stage disease, significant comorbidities, or demonstrated need for ...
(Date:7/10/2014)... , July 10, 2014  BC Technical, the largest ... MiE America , Inc., a leading provider of Siemens ... a long-term agreement naming BC Technical as the authorized ... MiE and BC Technical announced today that ... establish BC Technical as the service and systems provider ...
Breaking Medicine Technology:Veran Medical Publishes Lung Cancer Patient Management Study 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2
... will evaluate R7128 1000mg BID in HCV genotype 1, ... 2 or 3 ... treatment-experienced patients -, PRINCETON, N.J., May 14 ... additional cohorts of a 4-week,Phase 1 study of R7128 in ...
... (Nasdaq: KOSN ) today announced that updated data ... from a Phase,2 trial in combination with Herceptin(R) in ... Meeting of the American,Society of Clinical Oncology (ASCO), being ... 3, 2008., Abstract 1027, titled, "Phase 2 trial ...
Cached Medicine Technology:Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C 2Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C 3Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C 4Kosan Announces Data Presentations at ASCO 2008 Annual Meeting 2Kosan Announces Data Presentations at ASCO 2008 Annual Meeting 3
(Date:7/13/2014)... The North American water storage systems market is estimated ... by 2018, at a CAGR of 21.0%, from 2013 to ... rapid pace in North America. The U.S. is experiencing high ... wastewater storage and collection, and the increased spending on modernization ... a healthy rate in Canada, and is rising at a ...
(Date:7/13/2014)... July 13, 2014 Advanced boilers ... the least amount of fossil fuels, produce high-capacity ... Due to increased global warming and climate change ... to reduce harmful gas emissions and pollutants coming ... market in the global advance boilers market., The ...
(Date:7/13/2014)... MarketsandMarkets recently conducted a study ... Scanning; 3D rendering; Layout and Animation; Image Reconstruction]: ... 2018)”, which analyzes and studies the major market ... Europe, Eastern Europe, Middle East and Africa, Asia-Pacific ... competitive landscape of the 3D imaging market, providing ...
(Date:7/13/2014)... July 13, 2014 The Pearland, Texas location ... in age from four months to 12 years of age ... classes to birthday parties and Summer Camps, is now under ... Gym of Pearland after spending over six years at ... including Gym Director. , Berry has over ten years ...
(Date:7/13/2014)... July 13, 2014 Recently, 2014QuinceaneraDresses.com, ... has unveiled its new range of gorgeous ... market, the demand for elegant Quinceanera outfits is ... beautiful items. All the company’s newly released dresses ... They are all elegant and vivid. , ...
Breaking Medicine News(10 mins):Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 2Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 3Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 2Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2
... sight, researchers say, , TUESDAY, Sept. 15 (HealthDay News) ... for people who suffer vision loss when the large ... extremely compelling results, because a large, longer-term clinical trial ... vein occlusion could experience a visual improvement with treatment," ...
... of virus may last up to a week , TUESDAY, ... seem to be contagious longer than patients with ordinary seasonal ... what impact the findings will have on health-care experts, recommendations ... to produce relatively mild infections in most people and recovery ...
... a nonprofit organization, and the Dartmouth Psychiatric Research ... of evidence-based practiceshave announced a partnership to develop ... and addiction treatment industries. These resources, including curricula, ... published under a new "Dartmouth PRCHazelden" imprint. ...
... activity patterns may explain why some people are able to ... according to a new study by researchers with The Miriam ... have kept the weight off for several years were shown ... areas of the brain associated with behavioral control and visual ...
... , 78 percent of Americans see pharmaceutical ... Calif., Sept. 15 The Greenlining Institute ( www.greenlining.org ... Consulting Group which shows that Americans are losing confidence in the ... The national poll found that an overwhelming number of poll respondents ...
... , , , ... Sept. 15 The upcoming Transcatheter Cardiovascular Therapeutics (TCT) Conference, to ... a backdrop for the presentation of EVEREST registry clinical results of ... the most common type of heart valve insufficiency in the United ...
Cached Medicine News:Health News:People With Swine Flu May Be Contagious Longer Than Thought 2Health News:People With Swine Flu May Be Contagious Longer Than Thought 3Health News:Hazelden and Dartmouth Psychiatric Research Center form publishing partnership 2Health News:Brain's response to seeing food may be linked to weight loss maintenance 2Health News:Survey Finds Overwhelming Majority of Americans Believe Special Interests Hindering Health Care Reform 2Health News:Ongoing Progress of MitraClip(R) Therapy Highlighted at TCT 2009 2Health News:Ongoing Progress of MitraClip(R) Therapy Highlighted at TCT 2009 3Health News:Ongoing Progress of MitraClip(R) Therapy Highlighted at TCT 2009 4
DAVINCI® performs all required steps primary tube sampling, reagent dispensing, microplate incubation, washing and optical reading....
Inquire...
... IGFBP-3 contains 266 amino acids and is variably ... weight estimates of between 43 and 56 kDa. ... IGF-II with high affinity but do not bind ... structurally characterized at this time, IGFBP-3 has been ...
... handle up to 180'000 tests per year ... plates and is capable of processing up ... All assay steps, from loading of the ... controlled by Windows™-based software. Between 119 (standard ...
Medicine Products: